Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers

被引:2
作者
Lorch, Ulrike [1 ]
Pierscionek, Tomasz [1 ]
Freier, Anne [2 ]
Spencer, Christopher S. [2 ]
Taubel, Jorg [1 ,3 ]
机构
[1] St Georges Univ London, Richmond Pharmacol Ltd, Cranmer Terrace, London, England
[2] Richmond Res Inst, London, England
[3] St Georges Univ London, London, England
来源
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2021年 / 10卷 / 03期
关键词
bioequivalence; dose proportionality; fentanyl; Japanese; pharmacokinetic; phase; 1; transdermal patch; DELIVERY-SYSTEM; PHARMACOKINETICS; EFFICACY; VARIABILITY; DRUG; METABOLISM; TRIAL;
D O I
10.1002/cpdd.846
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two open-label, single-dose, randomized crossover studies were conducted in healthy Japanesemen to (1) assess dose proportionality of 5 doses (1.38, 2.75, 5.5, 8.25, and 11.0 mg) of Lafenta, a novel matrix-type transdermal fentanyl patch with a rate-controlling membrane; and (2) compare patch bioequivalence (11.0 mg) with a commercially available reference patch (Durotep MT Patch [16.8 mg]). Pharmacokinetics, adhesion performance, residual fentanyl, and safety parameters were assessed. Increases in mean AUC(0-t)and C(max)after application of the test patch were dose proportional. The test patch (11.0 mg) was bioequivalent to the 16.8-mg reference patch in terms of mean AUC(0-inf), AUC(0-t), and C-max. Residual fentanyl levels 72 hours postapplication were lower in the test than in the reference patch. Differences in adhesion performance between the test and the reference patch did not affect delivery efficacy and reliability of the novel matrix patch. Safety findings were in line with previous experiences with fentanyl. Both studies showed low variation in fentanyl exposure and delivery via the test patch. The test patch provided equivalent fentanyl exposure at a lower dose than the reference patch formulation with lower variability and the potential to lower medicinal waste.
引用
收藏
页码:260 / 271
页数:12
相关论文
共 31 条
[1]   Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life [J].
Ahmedzai, S ;
Brooks, D .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) :254-261
[2]   Chronic pain patients are impaired on an emotional decision-making task [J].
Apkarian, AV ;
Sosa, Y ;
Krauss, BR ;
Thomas, PS ;
Fredrickson, BE ;
Levy, RE ;
Harden, RN ;
Chialvo, DR .
PAIN, 2004, 108 (1-2) :129-136
[3]   Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects [J].
Cawello, Willi ;
Kim, Seong R. ;
Braun, Marina ;
Elshoff, Jan-Peer ;
Ikeda, Junji ;
Funaki, Tomoo .
CLINICAL DRUG INVESTIGATION, 2014, 34 (02) :95-105
[4]   Adhesive properties: a critical issue in transdermal patch development [J].
Cilurzo, Francesco ;
Gennari, Chiara G. M. ;
Minghetti, Paola .
EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (01) :33-45
[5]   Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers [J].
Darwish, M ;
Tempero, K ;
Kirby, M ;
Thompson, J .
CLINICAL PHARMACOKINETICS, 2005, 44 (12) :1279-1286
[6]   Risk factors for severe respiratory depression from prescription opioid overdose [J].
Fox, Lindsay M. ;
Hoffman, Robert S. ;
Vlahov, David ;
Manini, Alex F. .
ADDICTION, 2018, 113 (01) :59-66
[7]   Addressing the Fentanyl Threat to Public Health [J].
Frank, Richard G. ;
Pollack, Harold A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :605-607
[8]  
Gough K., 1995, Drug Inf J, V29, P1039, DOI DOI 10.1177/009286159502900324
[9]   Transdermal Matrix Fentanyl Membrane Patch (Matrifen®) In Severe Cancer-Related Chronic Pain [J].
Hair, Philip I. ;
Keating, Gillian M. ;
McKeage, Kate .
DRUGS, 2008, 68 (14) :2001-2009
[10]   Transdermal fentanyl - A review of its pharmacological properties and therapeutic efficacy in pain control [J].
Jeal, W ;
Benfield, P .
DRUGS, 1997, 53 (01) :109-138